Hospital-acquired Pneumonia (HAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Hospital-acquired Pneumonia (HAP) Market Outlook

Thelansis’s “Hospital-acquired Pneumonia (HAP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hospital-acquired Pneumonia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hospital-acquired Pneumonia (HAP) Overview

Hospital-acquired Pneumonia (HAP), or Nosocomial pneumonia, is characterized by the onset of pneumonia 48 hours or more after a patient's admission to the hospital without being present upon entry. Ventilator-associated pneumonia (VAP) is a specific type of HAP in intensive care units (ICUs) and represents a significant subset. The primary pathogens responsible for HAP and VAP are aerobic gram-negative bacilli (such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Enterobacter spp, and Acinetobacter spp) and gram-positive cocci (including Staphylococcus aureus, including methicillin-resistant S. aureus, and Streptococcus spp). The specific causative pathogens can vary depending on host factors and the microbial flora present in the hospital setting. Symptoms of HAP and VAP may include cough, expectoration, increased body temperature, chest pain, or difficulty breathing. Clinical signs can include fever, rapid breathing, areas of lung consolidation, or abnormal lung sounds known as crackles. The differential diagnosis for HAP and VAP includes various potential pathogens and conditions, such as Acinetobacter, Adenovirus, bacterial sepsis, burn wound infections, Clostridioides, colitis, croup, Enterobacter infections, Enterococcal infections, and E. coli infections.

• HAP is associated with a heightened risk of mortality. Studies have reported all-cause mortality rates ranging from 20% to 50% for VAP. Factors contributing to increased mortality include the severity of illness at the time of diagnosis (e.g., shock, coma, respiratory failure, acute respiratory distress syndrome), bacteremia, and underlying coexisting medical conditions.
• HAP occurs at a frequency of 5 to 10 cases per 1000 hospital admissions and is considered the most prevalent type of hospital-acquired infection in Europe and the United States. More than 90% of pneumonia cases in ICUs occur in intubated patients receiving mechanical ventilation.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: